Erasca Inc(NASDAQ:ERAS) 
Erasca is a clinical-stage, precision oncology company with a bold mission—to erase cancer. ... Our robust, rapidly advancing pipeline of promising therapeutic candidates has the potential to improve the treatment of a range of RAS/MAPK pathway-related cancers—and in turn, transform millions of live...
Website: https://www.erasca.com/
Founded: 2018
Full Time Employees: 102
CEO / Co-Founder: Jonathan E. Lim
Sector:
Industry:
Share this website to your friends
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
| Unit: USD | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
operating expenses: | |||||||||||||||||||
research and development | 27,265,000 | 23,241,000 | 22,474,000 | 21,170,000 | 25,969,000 | 26,122,000 | 27,631,000 | 33,032,000 | 28,574,000 | 24,805,000 | 25,213,000 | 26,218,000 | 27,585,000 | 28,184,000 | 27,488,000 | 27,429,000 | 24,128,000 | 19,951,000 | 17,598,000 |
in-process research and development | 150,000,000 | 2,000,000 | 7,500,000 | 22,500,000 | 2,000,000 | 1,680,000 | 5,488,000 | ||||||||||||
general and administrative | 10,646,000 | 9,363,000 | 10,072,000 | 9,455,000 | 9,661,000 | 9,590,000 | 9,611,000 | 12,250,000 | 10,277,000 | 9,067,000 | 9,445,000 | 9,752,000 | 9,440,000 | 8,778,000 | 8,417,000 | 7,076,000 | 6,920,000 | 6,916,000 | 5,098,000 |
total operating expenses | 187,911,000 | 32,604,000 | 34,546,000 | 38,125,000 | 35,630,000 | 35,712,000 | 37,242,000 | 67,782,000 | 38,851,000 | 33,872,000 | 34,658,000 | 35,970,000 | 37,025,000 | 36,962,000 | 35,905,000 | 36,505,000 | 31,048,000 | 46,044,000 | 28,184,000 |
income from operations | -187,911,000 | -32,604,000 | -34,546,000 | -38,125,000 | -35,630,000 | -35,712,000 | -37,242,000 | -67,782,000 | -38,851,000 | -33,872,000 | -34,658,000 | -35,970,000 | -37,025,000 | -36,962,000 | -35,905,000 | -36,505,000 | -31,048,000 | -46,044,000 | -28,184,000 |
yoy | 427.40% | -8.70% | -7.24% | -43.75% | -8.29% | 5.43% | 7.46% | 88.44% | 4.93% | -8.36% | -3.47% | -1.47% | 19.25% | -19.72% | 27.39% | ||||
qoq | 476.34% | -5.62% | -9.39% | 7.00% | -0.23% | -4.11% | -45.06% | 74.47% | 14.70% | -2.27% | -3.65% | -2.85% | 0.17% | 2.94% | -1.64% | 17.58% | -32.57% | 63.37% | |
other income | 22,000 | -48,500 | -37,000 | -88,250 | 173,000 | ||||||||||||||
interest income | 4,449,000 | 3,566,000 | 3,971,000 | 4,330,000 | 4,740,000 | 5,283,000 | 5,869,000 | 5,041,000 | 3,900,000 | 4,238,000 | 4,346,000 | 4,251,000 | 3,877,000 | 1,522,000 | 388,000 | 114,000 | 80,000 | 49,000 | 31,000 |
total other income | 4,471,000 | 3,512,000 | 3,934,000 | 4,249,000 | 4,664,000 | 3,480,000 | 6,042,000 | 4,581,000 | 3,834,000 | 4,171,000 | 4,297,000 | 4,189,000 | 3,826,000 | 1,473,000 | 297,000 | 47,000 | 584,000 | -25,000 | -30,000 |
net income | -183,440,000 | -29,092,000 | -30,612,000 | -33,876,000 | -30,966,000 | -32,232,000 | -31,200,000 | -63,201,000 | -35,017,000 | -29,701,000 | -30,361,000 | -31,781,000 | -33,199,000 | -35,489,000 | -35,608,000 | -36,458,000 | -30,464,000 | -46,069,000 | -28,214,000 |
yoy | 492.39% | -9.74% | -1.88% | -46.40% | -11.57% | 8.52% | 2.76% | 98.86% | 5.48% | -16.31% | -14.74% | -12.83% | 8.98% | -22.97% | 26.21% | ||||
qoq | 530.55% | -4.97% | -9.64% | 9.40% | -3.93% | 3.31% | -50.63% | 80.49% | 17.90% | -2.17% | -4.47% | -4.27% | -6.45% | -0.33% | -2.33% | 19.68% | -33.87% | 63.28% | |
net income per share | -0.6 | -0.1 | -0.11 | -0.12 | -0.11 | -0.09 | -0.11 | -0.29 | -0.23 | -0.19 | -0.2 | -0.21 | -0.22 | -0.29 | -0.3 | -0.31 | 0.05 | -0.46 | -1.2 |
weighted-average shares of common stock used in computing net loss per share, basic and diluted | 304,317,460 | 283,533,696 | 283,681,570 | 283,355,730 | 283,260,289 | 233,817,916 | 282,384,964 | 217,806,567 | 151,161,741 | 150,184,994 | 150,450,201 | 150,037,029 | 149,504,216 | 120,798,322 | 120,193,973 | 119,491,433 | 66,290,592 | 99,127,286 | 23,546,390 |
other comprehensive income: | |||||||||||||||||||
unrealized gain on marketable securities | -1,327 | -21 | 234 | -213 | 223 | -1,420 | 2,021 | 14 | -287 | 652 | 218 | -279 | 527 | -156 | |||||
comprehensive loss | -184,767 | -29,113 | -30,378 | -34,089 | -30,743 | -33,652 | -29,179 | -63,187 | -35,304 | -29,049 | -30,143 | -32,060 | -32,672 | -35,645 | -35,880 | -37,247 | -30,626 | -46,068 | -28,216 |
other expense | -81,000 | -76,000 | -460,000 | -66,000 | -67,000 | -49,000 | -62,000 | -51,000 | -49,000 | -91,000 | -67,000 | -47,500 | -74,000 | -61,000 | |||||
contribution of common stock to erasca foundation | 17,497,000 | ||||||||||||||||||
change in fair value of preferred stock purchase right liability | |||||||||||||||||||
unrealized loss on marketable securities | -272 | -789 | |||||||||||||||||
unrealized gain on investments | -0.5 | 1 | -2 |
Balance Sheets:
Quarterly
Annual
| Unit: USD | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
assets | |||||||||||||||||||
current assets: | |||||||||||||||||||
cash and cash equivalents | 47,256,000 | 73,805,000 | 70,230,000 | 66,143,000 | 70,482,000 | 67,739,000 | 68,885,000 | 172,802,000 | 76,726,000 | 93,075,000 | 112,862,000 | 138,787,000 | 272,756,000 | 219,260,000 | 298,007,000 | 333,347,000 | 360,487,000 | 445,811,000 | 156,396,000 |
short-term marketable securities | 196,532,000 | 202,270,000 | 218,170,000 | 234,518,000 | 234,103,000 | 230,570,000 | 250,027,000 | 235,610,000 | 220,959,000 | 219,275,000 | 183,806,000 | 178,458,000 | 116,985,000 | 136,668,000 | 73,469,000 | 59,186,000 | |||
prepaid expenses and other current assets | 9,996,000 | 10,164,000 | 11,525,000 | 9,999,000 | 10,032,000 | 10,484,000 | 11,262,000 | 9,593,000 | 8,938,000 | 8,326,000 | 9,298,000 | 6,606,000 | 8,142,000 | 9,823,000 | 9,945,000 | 10,841,000 | 5,542,000 | 5,668,000 | 3,618,000 |
total current assets | 253,784,000 | 286,239,000 | 299,925,000 | 310,660,000 | 314,617,000 | 308,793,000 | 330,174,000 | 418,005,000 | 306,623,000 | 320,676,000 | 305,966,000 | 323,851,000 | 397,883,000 | 365,751,000 | 381,421,000 | 403,374,000 | 420,017,000 | 492,313,000 | 197,291,000 |
long-term marketable securities | 164,719,000 | 65,721,000 | 73,982,000 | 86,088,000 | 106,492,000 | 142,164,000 | 144,391,000 | 51,836,000 | 9,642,000 | 46,891,000 | 48,079,000 | 9,569,000 | 19,313,000 | 29,224,000 | |||||
property and equipment | 12,612,000 | 13,303,000 | 14,037,000 | 14,825,000 | 15,587,000 | 16,321,000 | 17,153,000 | 17,990,000 | 21,358,000 | 22,327,000 | 23,229,000 | 23,908,000 | 24,621,000 | 24,875,000 | 24,191,000 | 20,405,000 | 15,954,000 | 8,520,000 | 2,257,000 |
operating lease assets | 28,265,000 | 29,030,000 | 30,081,000 | 30,814,000 | 31,525,000 | 32,218,000 | 32,891,000 | 33,546,000 | 37,177,000 | 37,861,000 | 38,524,000 | 39,168,000 | 39,794,000 | 41,051,000 | 14,778,000 | 16,932,000 | 17,356,000 | 19,042,000 | 1,877,000 |
restricted cash | 408,000 | 408,000 | 408,000 | 408,000 | 408,000 | 408,000 | 408,000 | 408,000 | 408,000 | 408,000 | 408,000 | 408,000 | 408,000 | 408,000 | 408,000 | 408,000 | 408,000 | 408,000 | 408,000 |
other assets | 1,446,000 | 1,453,000 | 1,968,000 | 2,591,000 | 2,615,000 | 2,622,000 | 3,879,000 | 3,959,000 | 4,456,000 | 4,383,000 | 4,388,000 | 5,248,000 | 4,836,000 | 4,775,000 | 4,712,000 | 5,126,000 | 2,910,000 | 1,665,000 | 3,550,000 |
total assets | 461,234,000 | 396,154,000 | 420,401,000 | 445,386,000 | 471,244,000 | 502,526,000 | 528,896,000 | 525,744,000 | 370,022,000 | 395,297,000 | 419,406,000 | 440,662,000 | 467,542,000 | 446,429,000 | 444,823,000 | 475,469,000 | 501,415,000 | 521,948,000 | 210,383,000 |
liabilities and stockholders' equity | |||||||||||||||||||
current liabilities: | |||||||||||||||||||
accounts payable | 2,163,000 | 981,000 | 3,029,000 | 1,663,000 | 2,262,000 | 468,000 | 2,405,000 | 2,142,000 | 2,633,000 | 2,000,000 | 3,701,000 | 2,631,000 | 3,353,000 | 4,319,000 | 2,291,000 | 4,712,000 | 4,677,000 | 1,324,000 | 1,507,000 |
accrued expenses and other current liabilities | 19,250,000 | 22,464,000 | 20,798,000 | 21,779,000 | 18,418,000 | 26,308,000 | 23,170,000 | 18,465,000 | 16,577,000 | 20,186,000 | 19,211,000 | 16,991,000 | 19,052,000 | 22,332,000 | 19,827,000 | 16,665,000 | 21,419,000 | 17,400,000 | 15,519,000 |
operating lease liabilities | 5,251,000 | 5,066,000 | 4,885,000 | 4,709,000 | 4,791,000 | 4,619,000 | 4,450,000 | 4,286,000 | 4,126,000 | 3,970,000 | 3,818,000 | 3,670,000 | 3,118,000 | 1,028,000 | 201,000 | 14,000 | 285,000 | 864,000 | 888,000 |
total current liabilities | 26,664,000 | 28,511,000 | 28,712,000 | 28,151,000 | 25,471,000 | 31,395,000 | 30,025,000 | 24,893,000 | 30,243,000 | 26,156,000 | 26,730,000 | 23,292,000 | 25,523,000 | 27,679,000 | 22,319,000 | 21,391,000 | 26,381,000 | 19,588,000 | 17,914,000 |
operating lease liabilities, net of current portion | 40,702,000 | 42,073,000 | 43,408,000 | 44,714,000 | 46,020,000 | 47,270,000 | 48,489,000 | 49,682,000 | 50,811,000 | 51,889,000 | 52,940,000 | 53,968,000 | 54,937,000 | 53,431,000 | 27,437,000 | 29,416,000 | 18,506,000 | 19,369,000 | 1,668,000 |
other liabilities | 340,000 | 399,000 | 395,000 | 263,000 | 251,000 | 362,000 | 340,000 | 82,000 | 559,000 | 566,000 | 761,000 | 697,000 | 630,000 | ||||||
total liabilities | 67,706,000 | 70,983,000 | 72,515,000 | 73,128,000 | 71,742,000 | 79,027,000 | 78,854,000 | 74,657,000 | 81,613,000 | 78,611,000 | 80,431,000 | 77,957,000 | 81,090,000 | 81,110,000 | 49,756,000 | 50,807,000 | 44,887,000 | 38,957,000 | 19,582,000 |
commitments and contingencies | |||||||||||||||||||
stockholders' equity: | |||||||||||||||||||
preferred stock, 0.0001 par value... | |||||||||||||||||||
common stock, 0.0001 par value... | 31,000 | 28,000 | 28,000 | 28,000 | 28,000 | 28,000 | 28,000 | 27,000 | 15,000 | 15,000 | 15,000 | 15,000 | 15,000 | 12,000 | 12,000 | 12,000 | 12,000 | 12,000 | 3,000 |
additional paid-in capital | 1,469,845,000 | 1,216,724,000 | 1,210,326,000 | 1,204,320,000 | 1,197,475,000 | 1,190,729,000 | 1,183,620,000 | 1,155,487,000 | 929,634,000 | 922,607,000 | 915,847,000 | 909,434,000 | 901,121,000 | 712,407,000 | 706,510,000 | 700,225,000 | 694,844,000 | 690,681,000 | 11,634,000 |
accumulated other comprehensive income | -699,000 | 628,000 | 649,000 | 415,000 | 628,000 | 405,000 | 1,825,000 | -196,000 | -210,000 | 77,000 | -162,000 | -1,000 | |||||||
accumulated deficit | -1,075,649,000 | -892,209,000 | -863,117,000 | -832,505,000 | -798,629,000 | -767,663,000 | -735,431,000 | -704,231,000 | -641,030,000 | -606,013,000 | -576,312,000 | -545,951,000 | -514,170,000 | -345,721,000 | -310,232,000 | -274,624,000 | -238,166,000 | -207,702,000 | -161,633,000 |
total stockholders' equity | 393,528,000 | 325,171,000 | 347,886,000 | 372,258,000 | 399,502,000 | 423,499,000 | 450,042,000 | 451,087,000 | 288,409,000 | 316,686,000 | 338,975,000 | 362,705,000 | 386,452,000 | 365,319,000 | 395,067,000 | 424,662,000 | 456,528,000 | 482,991,000 | |
total liabilities and stockholders' equity | 461,234,000 | 396,154,000 | 420,401,000 | 445,386,000 | 471,244,000 | 502,526,000 | 528,896,000 | 525,744,000 | 370,022,000 | 395,297,000 | 419,406,000 | 440,662,000 | 467,542,000 | 446,429,000 | 444,823,000 | 475,469,000 | |||
proceeds from prepayment of private placement | 6,907,000 | ||||||||||||||||||
accumulated other comprehensive loss | -575,000 | -793,000 | -514,000 | -1,379,000 | -1,223,000 | -951,000 | |||||||||||||
short-term investments | 53,988,000 | 40,834,000 | 37,277,000 | ||||||||||||||||
long-term investments | 44,770,000 | 5,000,000 | |||||||||||||||||
liabilities, convertible preferred stock and stockholders' equity | |||||||||||||||||||
preferred stock purchase right liability | |||||||||||||||||||
convertible preferred stock (series a, b-1 and b-2), 0.0001 par value... | 340,798,000 | ||||||||||||||||||
stockholders' equity | |||||||||||||||||||
total liabilities, convertible preferred stock and stockholders' equity | 501,415,000 | 521,948,000 | |||||||||||||||||
liabilities, convertible preferred stock and stockholders' deficit | |||||||||||||||||||
stockholders' deficit: | |||||||||||||||||||
total stockholders' deficit | -149,997,000 | ||||||||||||||||||
total liabilities, convertible preferred stock and stockholders' deficit | 210,383,000 |
Cashflow Statements:
Quarterly
Annual
| Unit: USD | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash flows from operating activities: | |||||||||||||||||
net loss | -183,440,000 | -30,612,000 | -33,876,000 | -30,966,000 | -31,200,000 | -63,201,000 | -35,017,000 | -30,361,000 | -31,781,000 | -33,199,000 | -35,489,000 | -35,608,000 | -36,458,000 | -46,069,000 | |||
adjustments to reconcile net loss to net cash from operating activities: | |||||||||||||||||
depreciation and amortization | 723,000 | 755,000 | 787,000 | 822,000 | 832,000 | 842,000 | 1,133,000 | 998,000 | 942,000 | 941,000 | 955,000 | 894,000 | 771,000 | 534,000 | 403,000 | 320,000 | 191,000 |
stock-based compensation expense | 8,460,000 | 5,965,000 | 6,398,000 | 6,713,000 | 6,308,000 | 6,637,000 | 7,180,000 | 6,848,000 | 6,136,000 | 6,238,000 | 7,012,000 | 6,845,000 | 5,232,000 | 5,055,000 | 4,442,000 | 2,883,000 | 3,017,000 |
in-process research and development expenses | 150,000,000 | 2,000,000 | 0 | 0 | 0 | 0 | 2,000,000 | 0 | 1,680,000 | ||||||||
accretion on marketable securities | -746,000 | -1,022,000 | -1,499,000 | -1,986,000 | -2,353,000 | -2,518,000 | -2,377,000 | -2,342,000 | -2,195,000 | ||||||||
realized gain from sales of marketable securities | -47,000 | ||||||||||||||||
changes in operating assets and liabilities: | |||||||||||||||||
prepaid expenses and other current and long-term assets | 175,000 | -903,000 | 57,000 | 459,000 | 202,000 | -1,759,000 | -333,000 | -507,000 | 977,000 | -1,832,000 | 1,124,000 | 670,000 | 59,000 | 944,000 | -5,515,000 | -1,119,000 | -2,094,000 |
accounts payable | 1,182,000 | 1,366,000 | -599,000 | 1,794,000 | -1,937,000 | 482,000 | -710,000 | 633,000 | -1,663,000 | 1,032,000 | -701,000 | 446,000 | 1,526,000 | -1,884,000 | 1,898,000 | 935,000 | -171,000 |
accrued expenses and other current and long-term liabilities | -3,269,000 | 1,190,000 | 1,378,000 | -8,006,000 | 3,238,000 | 5,471,000 | 1,313,000 | -3,626,000 | 952,000 | 2,468,000 | -1,358,000 | -4,363,000 | |||||
operating lease assets and liabilities | -421,000 | -397,000 | -677,000 | -385,000 | -377,000 | -374,000 | 257,000 | -238,000 | -236,000 | -236,000 | 209,000 | 3,324,000 | 548,000 | 820,000 | 11,063,000 | 783,000 | 512,000 |
net cash from operating activities | -27,383,000 | -21,658,000 | -20,531,000 | -31,555,000 | -24,564,000 | -22,419,000 | -29,183,000 | -33,251,000 | -24,788,000 | -24,120,000 | -25,951,000 | -26,358,000 | -23,945,000 | -27,141,000 | -25,806,000 | -22,482,000 | -23,219,000 |
capital expenditures | -36,000 | -6,000 | -30,000 | -83,000 | 0 | -5,000 | -13,000 | -123,000 | -219,000 | -252,000 | -1,168,000 | -2,129,000 | -4,705,000 | -6,012,000 | -3,905,000 | -2,893,000 | |
free cash flows | -27,419,000 | -21,664,000 | -20,561,000 | -31,638,000 | -24,564,000 | -22,424,000 | -29,196,000 | -24,911,000 | -24,339,000 | -26,203,000 | -27,526,000 | -26,074,000 | -31,846,000 | -31,818,000 | -26,387,000 | -26,112,000 | |
cash flows from investing activities: | |||||||||||||||||
purchases of marketable securities | -253,170,000 | -41,540,000 | -56,552,000 | -10,652,000 | -67,133,000 | -191,758,000 | -100,346,000 | -43,987,000 | -61,118,000 | -53,822,000 | -175,170,000 | -24,280,000 | -72,137,000 | -12,532,000 | -9,758,000 | ||
maturities of marketable securities | 58,550,000 | 71,250,000 | 77,827,000 | 45,000,000 | 89,750,000 | 89,325,000 | 36,250,000 | 54,000,000 | 65,745,000 | 52,250,000 | 66,750,000 | 60,200,000 | 18,700,000 | 7,900,000 | 19,300,000 | ||
sales of marketable securities | 100,826,000 | ||||||||||||||||
in-process research and development | -150,000,000 | -4,000,000 | 0 | 0 | 0 | 0 | 0 | -20,000,000 | 0 | 0 | -2,000,000 | 0 | -1,680,000 | ||||
purchases of property and equipment | -36,000 | -6,000 | -30,000 | -83,000 | 0 | -5,000 | -13,000 | -42,000 | -82,000 | -240,000 | -247,000 | -1,206,000 | -1,792,000 | -4,559,000 | -7,336,000 | -5,830,000 | -4,674,000 |
net cash from investing activities | -243,830,000 | 25,704,000 | 15,745,000 | 34,265,000 | 22,617,000 | -102,595,000 | -86,609,000 | 9,971,000 | 4,545,000 | -1,812,000 | -108,667,000 | 14,714,000 | -55,229,000 | -9,191,000 | -1,794,000 | -63,949,000 | -4,939,000 |
cash flows from financing activities: | |||||||||||||||||
proceeds from issuance of common stock in underwritten offering | 258,750,000 | ||||||||||||||||
issuance costs associated with underwritten offering | -16,044,000 | ||||||||||||||||
proceeds from the exercise of stock options | 1,958,000 | 41,000 | 43,000 | 33,000 | 396,000 | 311,000 | 105,000 | 24,000 | 193,000 | 7,000 | 122,000 | 183,000 | |||||
net cash from financing activities | 244,664,000 | 41,000 | 447,000 | 33,000 | 801,000 | 21,097,000 | 211,868,000 | 6,931,000 | 456,000 | 7,000 | 649,000 | 183,000 | 427,000 | 992,000 | 460,000 | 1,107,000 | 317,573,000 |
net increase in cash, cash equivalents, and restricted cash | -26,549,000 | ||||||||||||||||
cash, cash equivalents, and restricted cash at beginning of the period | 74,213,000 | ||||||||||||||||
cash, cash equivalents, and restricted cash at end of the period | 47,664,000 | ||||||||||||||||
impairment charge on operating lease assets and property and equipment | 0 | 0 | |||||||||||||||
impairment charge on investment in equity securities | 1,755,000 | 0 | |||||||||||||||
payment made for investment in equity securities | 0 | 0 | 0 | -2,000,000 | |||||||||||||
proceeds from issuance of common stock in private placement, net of fees and expenses | 0 | -33,000 | |||||||||||||||
proceeds from issuance of common stock in underwritten offering, net of discounts and offering costs | 0 | -212,000 | |||||||||||||||
proceeds from issuance of common stock in atm offering, net of commissions and expenses | 0 | ||||||||||||||||
proceeds from issuance of common stock under the employee stock purchase plan | 0 | 405,000 | 0 | 263,000 | 0 | 0 | |||||||||||
net increase in cash, cash equivalents and restricted cash | 4,087,000 | -4,339,000 | 2,743,000 | -78,747,000 | -35,340,000 | -27,140,000 | -85,324,000 | 289,415,000 | |||||||||
cash, cash equivalents and restricted cash at beginning of the period | 0 | 0 | 68,147,000 | 0 | 0 | 0 | 93,483,000 | 0 | 0 | 0 | 284,625,000 | 0 | 0 | 360,895,000 | 0 | 0 | |
cash, cash equivalents and restricted cash at end of the period | 4,087,000 | -4,339,000 | 70,890,000 | -1,146,000 | -103,917,000 | 96,076,000 | 77,134,000 | -19,787,000 | -25,925,000 | -133,969,000 | 273,164,000 | -78,747,000 | -35,340,000 | 333,755,000 | -85,324,000 | 289,415,000 | |
supplemental disclosure of noncash investing and financing activities: | |||||||||||||||||
vesting of early exercised options | 0 | 155,000 | 155,000 | 155,000 | 168,000 | 168,000 | 652,000 | 243,000 | 238,000 | 238,000 | 479,000 | 173,000 | 171,000 | ||||
obligation accrued for investment in equity securities | -157,000 | ||||||||||||||||
amounts accrued for in-process research and development | |||||||||||||||||
amounts accrued for offering costs | 67,000 | 178,000 | |||||||||||||||
amounts accrued for deferred offering costs | |||||||||||||||||
proceeds from prepayment of private placement | 6,907,000 | ||||||||||||||||
net income | |||||||||||||||||
adjustments to reconcile net income to net cash from operating activities: | |||||||||||||||||
net decrease in cash, cash equivalents and restricted cash | -1,146,000 | -16,349,000 | -19,787,000 | -25,925,000 | -133,969,000 | -11,461,000 | |||||||||||
amounts accrued for purchases of property and equipment | -41,000 | 21,000 | -5,000 | 38,000 | -337,000 | -146,000 | 1,324,000 | 1,925,000 | 1,781,000 | ||||||||
proceeds from the issuance of common stock in underwritten offering, net of discounts and offering costs | |||||||||||||||||
issuance of common stock in connection with license agreement | 0 | 0 | |||||||||||||||
operating lease assets obtained in exchange for lease obligation | 21,788,000 | 0 | |||||||||||||||
reduction in operating lease assets due to lease amendment | 0 | ||||||||||||||||
operating lease assets obtained in exchange for lease obligations | |||||||||||||||||
amortization on marketable securities | -1,411,000 | -975,000 | -174,000 | -12,000 | 17,000 | ||||||||||||
issuance of common stock to erasca foundation | 0 | ||||||||||||||||
change in fair value of preferred stock purchase right liability | 0 | 0 | |||||||||||||||
accrued expenses and other current liabilities | 3,582,000 | 3,010,000 | -3,656,000 | 4,686,000 | 2,189,000 | ||||||||||||
proceeds from the issuance of common stock in initial public offering, net of discounts and offering costs | 0 | ||||||||||||||||
proceeds from the issuance of convertible preferred stock, net of issuance costs | 0 | 0 | |||||||||||||||
proceeds from the exercise of stock options, net of repurchases | 427,000 | 375,000 | 460,000 | 40,000 | 21,000 | ||||||||||||
proceeds from the disgorgement of stockholder's short-swing profits | 0 | ||||||||||||||||
issuance of common stock in connection with asset acquisition | 0 | 0 | |||||||||||||||
conversion of preferred stock to common stock upon initial public offering | 0 | ||||||||||||||||
tenant improvement allowance included in operating lease liabilities | 0 | 6,483,000 | 0 | ||||||||||||||
supplemental disclosure of noncash operating activities: | |||||||||||||||||
amortization (accretion) on investments | |||||||||||||||||
gain on remeasurement of operating lease assets and liabilities | |||||||||||||||||
purchases of investments | -64,119,000 | -9,785,000 | |||||||||||||||
maturities of investments | 6,000,000 | 11,200,000 | |||||||||||||||
issuance of series b-2 convertible preferred stock in connection with asset acquisition | |||||||||||||||||
amounts accrued for in-process research and development expenses | |||||||||||||||||
preferred stock purchase right liability | |||||||||||||||||
amortization on investments | 29,000 | ||||||||||||||||
supplemental disclosure of cash flow information: | |||||||||||||||||
cash paid for taxes | |||||||||||||||||
supplemental disclosure of noncash investing and financing activity: |